OpenEvidence and Tandem Partner to Streamline Evidence-Based Prescribing and Prior Authorizations

Audio By Carbonatix

MIAMI & NEW YORK--(BUSINESS WIRE)--Apr 2, 2026--

OpenEvidence, the leader in AI-powered medical search and clinical decision support, and Tandem, the leader closing the gap between breakthrough medications and patient access, today announced a strategic partnership to dramatically accelerate how patients access lifesaving medications.

This collaboration directly connects evidence-based clinical decision-making with seamless prescription generation and prior authorization submission. The result is the elimination of delays for doctors and patients between diagnosis and treatment.

OpenEvidence empowers clinicians with real-time, continuously updated medical guidelines and research, enabling faster, more confident treatment decisions at the point of care. OpenEvidence powers more than 1 million clinical consultations per day in the United States alone, from logged-in, verified clinicians. Tandem turns those decisions into action, including automating prior authorizations and appeals, ensuring patient affordability, and routing each prescription to the preferred pharmacy or site of care, at no cost to providers or patients.

Together, the two platforms close one of healthcare’s most critical gaps: turning the right clinical decision into immediate patient access.

“Clinicians shouldn’t have to choose between delivering care and navigating administrative complexity,” said Ania Bilski, MD, VP of Clinical AI at OpenEvidence. “By partnering with Tandem, we’re removing friction from both clinical and operational workflows—so clinicians can focus on getting patients the right treatments, faster. We’re excited to partner with Tandem who has a similar mission to OpenEvidence to build great technology products and improve doctors' end to end experience, and ultimately drive the best patient outcomes.”

"As a practicing physician, I've seen how often the best treatment plans for patients are blocked by administrative complexity,” said Adam Harris, MD, Head of Clinical Intelligence at Tandem. “OpenEvidence helps clinicians make the right call. Tandem makes sure patients get the medicine they need. Together, we're closing a gap that has undercut doctors and limited patients for too long."

By unifying clinical intelligence with execution, OpenEvidence and Tandem are helping ensure that treatments reach patients faster, more reliably, and with less burden on providers. Together they are redefining how care is delivered.

About Tandem

Tandem is the AI-powered network automating prescription access so patients get life-changing treatment faster, medical staff get their time back, and providers can prescribe what they believe is best. Embedded directly into EHR workflows, Tandem automates every prior authorization from prescription to approval—generating appeals, routing prescriptions to the right pharmacy, and enrolling patients in savings and support programs to prevent cost-driven abandonment. Working across all drugs, all insurance plans, and all pharmacies nationwide, Tandem supports millions of patients annually and is trusted by clinicians across all 50 states, at no cost. Learn more at withtandem.com.

About OpenEvidence

OpenEvidence is the most widely used medical AI platform among U.S. physicians, and is trusted by hundreds of thousands of verified clinicians to make high-stakes clinical decisions at the point of care with answers that are sourced, cited, and grounded in peer-reviewed medical literature. OpenEvidence was founded with the mission to organize and expand the world's collective medical knowledge. Learn more at openevidence.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260402254260/en/

CONTACT: OpenEvidence

[email protected]

[email protected]

KEYWORD: FLORIDA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: TECHNOLOGY HOSPITALS HEALTH TECHNOLOGY SOFTWARE NETWORKS PRACTICE MANAGEMENT OTHER HEALTH GENERAL HEALTH HEALTH DATA MANAGEMENT

SOURCE: OpenEvidence

Copyright Business Wire 2026.

PUB: 04/02/2026 01:00 PM/DISC: 04/02/2026 01:02 PM

http://www.businesswire.com/news/home/20260402254260/en